Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.
Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease / M. Savarese, A. Torella, O. Musumeci, C. Angelini, G. Astrea, L. Bello, C. Bruno, G.P. Comi, G. Di Fruscio, G. Piluso, G. Di Iorio, M. Ergoli, G. Esposito, M. Fanin, O. Farina, C. Fiorillo, A. Garofalo, T. Giugliano, F. Magri, C. Minetti, M. Moggio, L. Passamano, E. Pegoraro, E. Picillo, S. Sampaolo, F.M. Santorelli, C. Semplicini, B. Udd, A. Toscano, L. Politano, V. Nigro. - In: NEUROMUSCULAR DISORDERS. - ISSN 0960-8966. - 28:7(2018 Jul), pp. 586-591. [10.1016/j.nmd.2018.03.011]
Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease
G.P. Comi;F. Magri;
2018
Abstract
Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.File | Dimensione | Formato | |
---|---|---|---|
savarese air.pdf
Open Access dal 04/04/2020
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
377.36 kB
Formato
Adobe PDF
|
377.36 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S096089661731489X-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
389.91 kB
Formato
Adobe PDF
|
389.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.